Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Fracción semipurificada de Ganoderma lucidum con actividad antitumoral

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20151023002
Publicado:
14/12/2015
Caducidad:
14/12/2016
Resumen:
Un grupo de investigación español ha obtenido una fracción de Ganoderma lucidum por cromatografía. Esta fracción puede ser útil para el desarrollo de nuevas formulaciones farmacéuticas en el tratamiento de la actividad tumoral de células cancerosas porque se ha detectado actividad citotóxica y células apoptóticas en linfoma murino y leucemia humana. El grupo busca compañías farmacéuticas con el fin de establecer acuerdos de cooperación técnica o de joint-venture.

Details

Tittle:
Semipurified fraction of Ganoderma lucidum with antitumour activity.
Summary:
A Spanish research group has obtained by chromatograpy a fraction from Ganoderma lucidum. This fraction can be useful for the development of new pharmaceutical formulations in the treatment of tumour activity of cancer. The group looks for technical cooperation or joint-venture agreements with pharmaceuticals companies.
Description:
Pharmaceutical and health care companies are looking for natural products with low toxicity to uses in their products. Ganoderma is a genus of polypore mushrooms extensively used in traditional asian medicines, and known for its potential in pharmaceutical uses, including anticancer drug such as human leukemia, lymphoma, etc ...

A spanish research group at a Madrid´s University have developed a technique for obtaining a Fraction of a Semipurified Active of cultivated fruiting bodies of Ganoderma Lucidum (FSAGL) by extraction in 10% methanol.

To learn the chemical elements that make up the FSAGL, i.e. to determine the elemental composition of the sample in both qualitative and quantitative elemental analysis was performed. The results of the analysis of the elements that compose the body FSAGL successful show consists mainly of carbon (about 50%) and oxygen (32.3%) and to a lesser extent, hydrogen and nitrogen.

The extract of Ganoderma lucidum is silica-gel column chromatography using mobile phase of butanol: acetic acid: water (3:1:1). The active fraction has a Rf of 0.7. This fraction was analyzed by HPLC-Mass. The active fraction is capable of inducing cell death in murine lymphoma and leukemic human tumour cells by promoting programmed cell death. It also causes changes in the levels of expression of apoptotic factors p53, Bcl2, Bax and the dephosphorylated and phosphorylated forms of intracellular kinases such as Erk and Akt.

This fraction can be useful for the development of new pharmaceutical formulations in the treatment of tumour activity of cancer cells since cytotoxic activity was detected and apoptotic cells in murine lymphoma and human leukemia.

The group is looking for technical cooperation or joint-venture agreements. They are looking for pharmaceutical companies.
Advantages and Innovations:
Innovations:

A fraction of compounds obtained from Ganoderma lucidum has been described. This fraction is active on murine lymphoma DA-1 cells and human leukemia NB4 cells. This fraction induced DNA (deoxyribonucleic acid) fragmentation, changes in cell membrane and cell death.
The innovation lies on the antitumor activity, the source of such compounds (the mushroom Ganoderma lucidum grown in stablished conditions developed in the lab).


Advantages:

The invention could be useful in developing new pharmaceutical formulae for treatment of antitumor activity of cancer and leukemia cells. The growth of Ganoderma lucidum and the process of isolation of the active fraction do not have big costs.
Stage of Development:
Under development/lab tested
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
National patent.

Partner sought

Type and Role of Partner Sought:
The group looks for joint venture agreements but it is also open to achieve technical cooperation agreements with pharmaceutical companies. The technical cooperation with the company could consist on providing the additional development of the technology necessary to reach a final product.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06004 Micro y nanotecnología relacionada con las ciencias biológicas
06002008 Microbiología